WO1988001166A1 - Stimulation de l'angiogenese et promotion de l'endothelialisation - Google Patents
Stimulation de l'angiogenese et promotion de l'endothelialisation Download PDFInfo
- Publication number
- WO1988001166A1 WO1988001166A1 PCT/AU1987/000256 AU8700256W WO8801166A1 WO 1988001166 A1 WO1988001166 A1 WO 1988001166A1 AU 8700256 W AU8700256 W AU 8700256W WO 8801166 A1 WO8801166 A1 WO 8801166A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inflammatory compound
- angiogenesis
- inflammatory
- proline
- composition
- Prior art date
Links
- 230000026341 positive regulation of angiogenesis Effects 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000033115 angiogenesis Effects 0.000 claims abstract description 25
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims abstract description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 7
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims abstract description 4
- BYHXLDZDSZVDJH-UHFFFAOYSA-N acetic acid;1,3-thiazole Chemical compound CC(O)=O.C1=CSC=N1 BYHXLDZDSZVDJH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 238000009792 diffusion process Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 claims description 4
- OMGHIGVFLOPEHJ-BYPYZUCNSA-N (2s)-2,5-dihydro-1h-pyrrole-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCC=C1 OMGHIGVFLOPEHJ-BYPYZUCNSA-N 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- 125000000174 L-prolyl group Chemical class [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 4
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 4
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 3
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 3
- 239000000835 fiber Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 12
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 9
- 229960001259 diclofenac Drugs 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 229960004369 flufenamic acid Drugs 0.000 description 7
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 210000001043 capillary endothelial cell Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000512 collagen gel Substances 0.000 description 4
- 230000010595 endothelial cell migration Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920003345 Elvax® Polymers 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 108010045569 atelocollagen Proteins 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003681 parotid gland Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- -1 Phenyl Thiazole acetic acid Chemical compound 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical class CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- This invention relates to the control of angiogenesis, and methods and compositions therefor.
- a method for stimulating angiogenesis in a mammal characterized by the use of an anti-inflammatory agent.
- 3T3-cell derived growth factor McAuslan et al. , 1980
- tumor-derived growth factor Klagsbrun et al.. , 1982
- ECGF endothelial cell growth stimulator
- concentrations of copper ions can induce neovascularisation in the anterior eye chamber or corneal pocket and also migration of endothelial cells in culture (McAuslan, 1979; McAuslan and Gole, 1980; McAuslan and Reilly, 1980).
- an ideal agent for control of angiogenesis should have a direct action, and should itself be anti-inflammatory.
- a further limitation is imposed by the necessity for the agent to penetrate the target organ.
- NB also called hydratropic acids 2— henylpropanoic acids
- a method of stimulating angiogenesis in a mammal comprising the step of administering to that animal an anti-in lammatory compound.
- a method of stimulating endothelialisation in a mammal comprising the step of administering to that mammal an anti-inflammatory compound.
- the anti-inflammatory compound is preferably selected from the group which includes salicylic acid, anthranilic acid, phenyl acetic acid, and thiazole acetic acid, and their angiogenically-active analogues and derivatives.
- the anti-inflammatory compound has a directly-acting angiogenic effect.
- the compound comprises an aromatic carboxylic acid group.
- the compound is administered so as to achieve a diffusion gradient of concentration to which endothelial cells respond.
- Combinations of two or more compounds according to the invention may optionally be used.
- Combinations of one or more compounds according to the invention together with one or more other stimulators of angiogenesis may also optionally be used.
- Said second stimulator is suitably a modulator of collagen synthesis or of collagen fibril assembly.
- the modulator is an inhibitor of the ' activity of the enzyme proline hydroxylase.
- the inhibitory agent is selected from the group which includes cis-4-hyroxy-L-proline, 3, 4-dehydro-L-proline, L-azetidine-2-carboxylic acid, L-proline analogues, and their angiogenically-active analogues and derivatives.
- said second stimulator of angiogenesis is epidermal growth factor or a pharmacologically active analogue, fragment or derivative thereof.
- the compound according to the invention may optionally be administered in a slow-release form or in a biodegradable matrix.
- the corneal pocket assay in rabbits as described by Gimbrone et al. (1974) was used according to the modification of McAuslan and Gole (1981).
- McAuslan et al_. , 9183 it is extremely difficult to distinguish a directly acting angiogenic stimulus from one which is mediated by leukocytes (McAuslan et al_. , 9183).
- endothelial cell migration is a primary event in neovascularisation, and since there is a correlation between the ability of certain metal ions to induce vascularisation and their ability to cause migration of cultured cells, such migration has been suggested (McAuslan 1979) as the basis for a quantitative assay of angiogenic activity. There is comparatively little information on the correlation between this activity and neovascularising activity, and furthermore, a number of unrelated substances will induce migration of cultured endothelial cells and neovascularisation (McAuslan- 1979) Proliferation of endothelial cells is thought to be a response secondary to cell migration during new vessel formation. There are reports of low-molecular-weight neovasculogenic activities that can stimulate proliferation of cultured endothelial cells. However, the proliferative responses have been marginal and the reports are not in accord as to the minimal conditions or cell type necessary.
- Each polymer fragment is impregnated with approximately 0.5 mg of the solid agent to be tested, so that the agent diffuses out of the polymer and sets up a concentration gradient which changes with time.
- the corneal pocket assay of Gimbrone et. a _ (1974) as modified by Gole and McAuslan (1981) was used on New Zealand white rabbits of 2-3kg body weight. Opposite eyes of each animal were used as control and test, respectively. The results were documented photographically and histologically 10 days postoperation.
- Anti-inflammatory agents were tested for angiogenic activity in the subcutaneous implant assay in rabbits as described above. The results are shown in Table 2. Both flufenamic acid and diclofenac showed strong activity in stimulating vascularization. Only one of twelve controls showed any activity, giving a weak response.
- Elvax pellets contained 0.05* mg test'-agent per mm , i.e. equivalent to 2 x 10 -4M.
- Diclofenac 10 "5 M 145 31.31 10 " ⁇ M 111 33.60 10 ⁇ 7 M 76 28.i ⁇
- the present invention is capable of application in a wide variety of clinical fields.
- Stimulation of angiogenesis can be used to enhance the healing of burns and wounds, especially those involving large tissue defects, acceptance of skin or organ grafts, and can also be used in reconstructive and cosmetic surgery, including the use of subdermal implants, and in prosthetic surgery, particularly that involving vascular prostheses.
- Such stimulation may be used in any situation wherein endothelial cell migration and regeneration of endothelium are advantageous, or where an increase in blood flow is desirable, e.g., stroke, heart disease, or foetal blood insufficiency.
- the method according to the invention could be used in the following situations: a) Where development of a capillary network would be advantageous, e.g. Surgical repair, wound healing, b) Where stimulation of endothelialisation would be advantageous, . e.g. Synthetic or natural graft materials. c) Where healing may be enhanced by either angiogenic or anti-inflammatory action, e.g. ImpIantable prosthetic devices.
- This application excludes the use of Diclofenac as an anti-inflammatory agent which might improve the performance of cardiac pacemaker electrodes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un procédé, permettant de stimuler l'angiogénèse ou l'endothélialisation chez un mammifère, consiste à administrer audit mammifère un composé anti-inflammatoire. Celui-ci a de préférence un effet angiogène agissant directement; les composés préférés comportent de l'acide salicyclique, de l'acide anthranilique, de l'acide acétique de phényle et de l'acide acétique de thiazole. Un composé anti-inflammatoire peut être administré en même temps qu'un second stimulateur de l'angiogénèse. Des compositions et des articles sont également revendiqués.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH752186 | 1986-08-18 | ||
| AUPH7521 | 1986-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1988001166A1 true WO1988001166A1 (fr) | 1988-02-25 |
Family
ID=3771766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU1987/000256 WO1988001166A1 (fr) | 1986-08-18 | 1987-08-10 | Stimulation de l'angiogenese et promotion de l'endothelialisation |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0318488A4 (fr) |
| JP (1) | JPH01503705A (fr) |
| WO (1) | WO1988001166A1 (fr) |
| ZA (1) | ZA876079B (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424193A2 (fr) * | 1989-09-22 | 1991-04-24 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | L'utilisation de l'actinonin pour la fabrication d'un médicament pour l'inhibition de l'angiogenèse |
| WO1998042329A1 (fr) * | 1997-03-21 | 1998-10-01 | Mitsubishi Chemical Corporation | Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale |
| US6660283B2 (en) * | 1997-12-19 | 2003-12-09 | Societe L'oreal S.A. | Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition |
| WO2004073717A1 (fr) * | 2003-02-21 | 2004-09-02 | Teikoku Seiyaku Co., Ltd. | Promoteur de la croissance de vaisseaux sanguins |
| US8790646B2 (en) | 2004-04-14 | 2014-07-29 | Genentech Inc. | Compositions and methods for modulating vascular development |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2515189A (en) * | 1948-10-12 | 1950-07-18 | Samson | Preservation of leucocytes in blood |
| GB1032253A (en) * | 1961-12-19 | 1966-06-08 | Fo We Forschungs Und Verwertun | Coumarin derivatives and process for the production thereof |
| US3873715A (en) * | 1973-04-06 | 1975-03-25 | Univ Miami | Therapeutic agent for improving cardiovascular function |
| US3928587A (en) * | 1974-08-16 | 1975-12-23 | Philip Nicholas Sawyer | Method of conditioning vascular systems by administering 3,5 dichloroaspirin and method of evaluating pharmaceutical compounds |
| US4132787A (en) * | 1975-05-30 | 1979-01-02 | Science Union Et Cie | Pharmaceutical compositions containing a gamma-resorcylic acid derivative in the treatment of thrombosis |
| US4545992A (en) * | 1981-08-14 | 1985-10-08 | Toko Yakuhin Industry Co., Ltd. | Pharmaceutical preparations |
| AU560035B2 (en) * | 1983-04-18 | 1987-03-26 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74715A0 (en) * | 1984-03-27 | 1985-06-30 | Univ New Jersey Med | Biodegradable matrix and methods for producing same |
| WO1987004925A1 (fr) * | 1986-02-18 | 1987-08-27 | Biota Scientific Management Pty. Ltd. | Stimulation de l'angiogenese |
-
1987
- 1987-08-10 EP EP19870905152 patent/EP0318488A4/fr not_active Withdrawn
- 1987-08-10 WO PCT/AU1987/000256 patent/WO1988001166A1/fr not_active Application Discontinuation
- 1987-08-10 JP JP62504759A patent/JPH01503705A/ja active Pending
- 1987-08-17 ZA ZA876079A patent/ZA876079B/xx unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2515189A (en) * | 1948-10-12 | 1950-07-18 | Samson | Preservation of leucocytes in blood |
| GB1032253A (en) * | 1961-12-19 | 1966-06-08 | Fo We Forschungs Und Verwertun | Coumarin derivatives and process for the production thereof |
| US3873715A (en) * | 1973-04-06 | 1975-03-25 | Univ Miami | Therapeutic agent for improving cardiovascular function |
| US3928587A (en) * | 1974-08-16 | 1975-12-23 | Philip Nicholas Sawyer | Method of conditioning vascular systems by administering 3,5 dichloroaspirin and method of evaluating pharmaceutical compounds |
| US4132787A (en) * | 1975-05-30 | 1979-01-02 | Science Union Et Cie | Pharmaceutical compositions containing a gamma-resorcylic acid derivative in the treatment of thrombosis |
| US4545992A (en) * | 1981-08-14 | 1985-10-08 | Toko Yakuhin Industry Co., Ltd. | Pharmaceutical preparations |
| AU560035B2 (en) * | 1983-04-18 | 1987-03-26 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
Non-Patent Citations (8)
| Title |
|---|
| DERWENT ABSTRACT Accession No. 1983-727103, Class B04, SU,A1, 959784 (Mosc Medial Stomat) 23 September 1982 (23.09.82) * |
| Derwent Soviet Inventions Illustrated, Vol. V, No. 49, issued 14 July 1975, Pharmaceuticals p. 7, SU 406393 (Tevlina) 10 July 1974 (10.07.74) * |
| McAUSLAN, B.R. and G.A. GOLE (1980) Trans. Ophthalmol. Soc. U.K. 100 (3) 354-358 * |
| PATENT ABSTRACTS OF JAPAN, C-105 page 35, JP,A, 57-024308 (NITTO DENKI KOGYO K.K.) 8 February 1982 (08.02.82) * |
| PATENT ABSTRACTS OF JAPAN, C-249 page 9, JP,A, 59-116218 (KOUWA K.K.) 5 July 1984 (05.07.84) * |
| PATENT ABSTRACTS OF JAPAN, C-316, page 68, JP,A, 60-139621 (GRELAN SEIYAKU K.K.) 24 July 1985 (24.07.85) * |
| PATENT ABSTRACTS OF JAPAN, C-360, page 86, JP,A, 61-044811 (SS Pharmaceut Co. Ltd) 4 March 1986 (04.03.86) * |
| See also references of EP0318488A4 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424193A2 (fr) * | 1989-09-22 | 1991-04-24 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | L'utilisation de l'actinonin pour la fabrication d'un médicament pour l'inhibition de l'angiogenèse |
| EP0424193A3 (en) * | 1989-09-22 | 1991-07-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Use of actinonin for angiogenesis inhibition |
| US5134156A (en) * | 1989-09-22 | 1992-07-28 | Zaidan Hojin Biseibutsu Kagaku Kai | Pharmaceutical composition and method for angiogenesis inhibition |
| WO1998042329A1 (fr) * | 1997-03-21 | 1998-10-01 | Mitsubishi Chemical Corporation | Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale |
| US6660283B2 (en) * | 1997-12-19 | 2003-12-09 | Societe L'oreal S.A. | Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition |
| WO2004073717A1 (fr) * | 2003-02-21 | 2004-09-02 | Teikoku Seiyaku Co., Ltd. | Promoteur de la croissance de vaisseaux sanguins |
| US8790646B2 (en) | 2004-04-14 | 2014-07-29 | Genentech Inc. | Compositions and methods for modulating vascular development |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA876079B (en) | 1988-06-29 |
| EP0318488A4 (fr) | 1990-02-26 |
| EP0318488A1 (fr) | 1989-06-07 |
| JPH01503705A (ja) | 1989-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5552162A (en) | Method for improvement of scar size and appearance | |
| TWI257307B (en) | Pharmaceutical composition for cardiac tissue repair | |
| US6287606B1 (en) | Methods of enhancing wound healing and tissue repair | |
| KR20050086949A (ko) | 콜라졸리를 사용한 조성물 및 방법 | |
| US5132119A (en) | Treatment of hypertrophic wound healing disorders with calcium channel blockers | |
| WO1994017839A9 (fr) | Procede d'amelioration de la taille et de l'aspect d'une cicatrice | |
| US5902609A (en) | Composition for the control of wound scar production | |
| US5036046A (en) | Method for enhancing healing of corneal endothelial wounds | |
| US5155038A (en) | Use of thrombospondin to promote wound healing | |
| US6191144B1 (en) | Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis | |
| Tripathi et al. | Prospects for epidermal growth factor in the management of corneal disorders | |
| US5051443A (en) | Method for enhancing healing of corneal endothelial wounds | |
| CA2246418A1 (fr) | Inhibiteur de la neoformation de vaisseaux sanguins | |
| CA2551525A1 (fr) | Composition pharmaceutique pour derives peptidiques de la thrombine | |
| CA2058597C (fr) | Compositions cicatrisantes a base de facteur de croissance de fibroblaste et d'acide ascorbique | |
| Liu et al. | Development of a thermosensitive hydrogel loaded with DTT and SDF-1 facilitating in situ periodontal bone regeneration | |
| JP3149180B2 (ja) | 瘢痕治療のためのカルシウム拮抗薬の使用 | |
| JP2001122800A (ja) | 骨シアロプロティンを含む結合組織修復促進組成物及び骨シアロプロティンの使用方法 | |
| WO1988001166A1 (fr) | Stimulation de l'angiogenese et promotion de l'endothelialisation | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| EA014296B1 (ru) | Средство, активирующее стволовые клетки и/или клетки-предшественники | |
| CA2485268A1 (fr) | Formulation pharmaceutique resorbable destinee a la liberation continue de thrombine | |
| EA001745B1 (ru) | Ингибитор вторичной катаракты | |
| WO1989001489A1 (fr) | Regulation de l'angiogenese et compositions et procedes prevus a cet effet | |
| Fossum et al. | TP508 (Chrysalin®) Reverses Endothelial Dysfunction and Increases Perfusion and Myocardial Function in Hearts With Chronic Ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1987905152 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1987905152 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1987905152 Country of ref document: EP |